Video

Safety Profile of S1P Receptor Modulators for Multiple Sclerosis

Author(s):

Krzysztof Selmaj, MD, PhD

Krzysztof Selmaj, MD, PhD, discusses the side effects of sphinogine-1-phospate (S1P) receptor modulators, highlighting particular adverse events clinicians should be aware of when treating multiple sclerosis (MS).

Related Videos
Robert J. Fox, MD
Robert J. Fox, MD
Bruce Bebo, PhD
Bruce Bebo, PhD
Joseph Kuchling, MD
Emilio Portaccio, MD
Related Content
MS Treatment Cladribine Provides Quality of Life Benefits and Improved Cognition Over 4-Year Period
February 27th 2025

MS Treatment Cladribine Provides Quality of Life Benefits and Improved Cognition Over 4-Year Period

Marco Meglio
Neurology Unwrapped: 2024’s Most Intriguing Conversations
December 27th 2024

Neurology Unwrapped: 2024’s Most Intriguing Conversations

Marco Meglio
Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS
February 27th 2025

Phase 4 Study to Test Switch From Anti-CD20 Therapy to Ozanimod in Stable MS

Marco Meglio
Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis
October 4th 2024

Episode 125: Understanding Major Changes to New McDonald Criteria for Multiple Sclerosis

Marco Meglio
This Week on NeurologyLive® — February 24, 2025
February 24th 2025

This Week on NeurologyLive® — February 24, 2025

NeurologyLive® Staff
NeurologyLive® Brain Games: February 23, 2025
February 23rd 2025

NeurologyLive® Brain Games: February 23, 2025

Marco Meglio
© 2025 MJH Life Sciences

All rights reserved.